This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 125 words of the full text and any section headings.

To the Editor: We have 2 concerns about the methodology of the trial reported by Dr Steinhubl and colleagues.¹

First, the authors used symptoms of angina pectoris as objective evidence of ischemia. In reality, symptoms of angina pectoris are subjective and may not correlate well with the presence of cardiac ischemia. Previous studies have used more objective criteria such as electrocardiographic changes or elevated biochemical markers of cardiac ischemia.²

Second, the study had 2 main objectives: to evaluate the benefit of long-term treatment with clopidogrel after PCI and to determine the benefit of initiating clopidogrel with a preprocedure loading dose, both in addition to aspirin therapy. It is not clear, however, how the authors adjusted their statistical tests for multiple comparisons arising from these hypotheses.

Javier Borja, MD; Iñaki Pérez, BS; Guillermo De la Cruz, MD
Clinical Research and Development Unit
J. Uriach & Cía
Palau-solita i Plegamans
Barcelona, Spain

1. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. FREE FULL TEXT 2. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Lancet. 1999;354:708-715. FULL TEXT | ISI | PUBMED

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289:1926.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Clopidogrel and Percutaneous Coronary Interventions
Robin P. Choudhury
JAMA. 2003;289(15):1925.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
John F. P. Bridges
JAMA. 2003;289(15):1925-1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
Brian Y. L. Wong and Eric A. Cohen
JAMA. 2003;289(15):1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions
Attila Dirkali and Victor A. Umans
JAMA. 2003;289(15):1926.
EXTRACT | FULL TEXT  

Clopidogrel and Percutaneous Coronary Interventions—Reply
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann, III, Edward T. A. Fry, Augustin DeLago, Charles Wilmer, and Eric J. Topol
JAMA. 2003;289(15):1926-1927.
EXTRACT | FULL TEXT  

Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann III, Edward T. A. Fry, Augustin DeLago, Charles Wilmer, Eric J. Topol, and for the CREDO Investigators
JAMA. 2002;288(19):2411-2420.
ABSTRACT | FULL TEXT